STOCK TITAN

Beyondspring Inc - BYSI STOCK NEWS

Welcome to our dedicated page for Beyondspring news (Ticker: BYSI), a resource for investors and traders seeking the latest updates and insights on Beyondspring stock.

BeyondSpring Inc (NASDAQ: BYSI) is a clinical-stage biopharmaceutical leader advancing innovative cancer therapies through its Plinabulin pipeline and target protein degradation research. This page serves as the definitive source for verified company updates, providing investors and researchers with essential insights into therapeutic developments and strategic initiatives.

Access timely announcements spanning clinical trial progress, regulatory milestones, and partnership agreements. Our curated collection includes press releases on Plinabulin's multifaceted mechanism of action, updates from global Phase 3 studies, and innovations from the SEED Therapeutics collaboration. Each update is vetted for accuracy to support informed decision-making.

Bookmark this resource for structured access to BeyondSpring's scientific advancements in immuno-oncology and protein degradation technology. Regular updates ensure you maintain current awareness of the company's progress in addressing unmet needs in NSCLC and other oncology indications.

Rhea-AI Summary

BeyondSpring (NASDAQ: BYSI) appointed Brendan Delaney to its Board of Directors, effective immediately. Delaney brings over 25 years of experience in commercial oncology drug launches, which is crucial as BeyondSpring's lead asset, plinabulin, is under FDA Priority Review for preventing chemotherapy-induced neutropenia, with a PDUFA date set for November 30, 2021. His expertise is expected to aid in the commercial launch planning, contingent on regulatory approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
-
Rhea-AI Summary

BeyondSpring announced its participation in the virtual William Blair Biotech Focus Conference on July 14-15, 2021. The company, focused on innovative cancer therapies, will be available for one-on-one meetings during the event. Their lead asset, plinabulin, is under review for preventing chemotherapy-induced neutropenia, with a PDUFA date of November 30, 2021, in the U.S. BeyondSpring’s pipeline includes pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, utilizing a targeted protein degradation discovery platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
conferences
-
Rhea-AI Summary

BeyondSpring announced an R&D Day on June 25, 2021, to discuss its immune agent Plinabulin for cancer treatment, particularly in non-small cell lung cancer. Key Opinion Leaders Steven Lin, M.D., and Trevor Feinstein, M.D., will present insights on the current treatment landscape. Topics include Plinabulin's FDA priority review for chemotherapy-induced neutropenia and ongoing pivotal studies. The company aims to address unmet medical needs in cancer therapy, with Plinabulin being central to their strategy, also exploring combinations with checkpoint inhibitors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
conferences
Rhea-AI Summary

BeyondSpring announced significant advancements regarding its lead drug, plinabulin, including a New Drug Application (NDA) filed with the FDA for priority review aimed at preventing chemotherapy-induced neutropenia (CIN). The FDA set a PDUFA date of November 30, 2021. Recent presentations revealed favorable PROTECTIVE-2 Phase 3 data, indicating plinabulin combined with G-CSF offers better outcomes than pegfilgrastim alone. The company also initiated clinical trials on plinabulin with checkpoint inhibitors for resistant tumors, showcasing promising Phase 1 data.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.03%
Tags
-
Rhea-AI Summary

BeyondSpring Inc. (NASDAQ: BYSI) will host a conference call on June 16, 2021, at 8:30 AM ET to discuss its Q1 2021 financial results and recent corporate updates. Investors can access the call by dialing 877-451-6152 (U.S.) or 201-389-0879 (International), using conference ID 13720525. A live webcast will be available on the company’s website, and an archived replay will be accessible for 90 days. BeyondSpring focuses on developing immuno-oncology therapies, with its lead asset, plinabulin, undergoing Priority Review for chemotherapy-induced neutropenia and being tested for anti-cancer benefits.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
conferences earnings
-
Rhea-AI Summary

BeyondSpring, a biopharmaceutical firm, showcased data from the PROTECTIVE-1 Phase 3 clinical trial of plinabulin at the ASCO Annual Meeting. Plinabulin demonstrated a non-inferior effectiveness against chemotherapy-induced neutropenia (CIN) compared to pegfilgrastim, with benefits including reduced febrile neutropenia and lower bone pain. The drug, which targets CIN prevention, received FDA's Priority Review for its NDA submission in the U.S. and China, with a PDUFA action date set for November 30, 2021. The study results highlighted plinabulin's fast action and potential market impact, especially amid rising CIN-related hospitalizations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
Rhea-AI Summary

BeyondSpring Inc. (NASDAQ: BYSI) announced a late-breaking poster presentation regarding plinabulin, demonstrating its efficacy in preventing chemotherapy-induced neutropenia (CIN) in combination with pegfilgrastim.

The Phase 3 PROTECTIVE-2 study showed significant improvements in immune profiles and CIN prevention compared to pegfilgrastim alone. The U.S. FDA accepted the New Drug Application with Priority Review, setting a PDUFA action date of November 30, 2021. With 110,000 annual hospitalizations due to CIN in the U.S., plinabulin is positioned to address this critical medical need, expanding its market potential significantly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
-
Rhea-AI Summary

BeyondSpring announced positive results from the PROTECTIVE-2 Phase 3 clinical trial of plinabulin combined with pegfilgrastim for preventing chemotherapy-induced neutropenia (CIN). The combination therapy demonstrated a 50% reduction in both the incidence and duration of febrile neutropenia (FN) compared to pegfilgrastim alone, with 3.6% incidence versus 6.3%. Additionally, it decreased hospitalization duration significantly to 3.75 days from 7.14 days. The data supports the combination's effectiveness in improving quality of life and has led to NDA submissions in the U.S. and China.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.27%
Tags
-
Rhea-AI Summary

BeyondSpring (NASDAQ: BYSI) announced the dosing of the first patient in a Phase 1b/2 trial studying plinabulin in combination with PD-1/PD-L1 inhibitors and radiation therapy for advanced cancers, including non-small cell lung cancer (NSCLC). This triple therapy could address resistance to immunotherapy, a significant unmet medical need. The study, led by Dr. Vivek Subbiah at MD Anderson Cancer Center, aims to evaluate safety and tolerability in patients who have progressed on prior treatments. Plinabulin has shown promise in overcoming resistance, with a notable 43% response rate in previous studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
Rhea-AI Summary

BeyondSpring announced that the FDA has accepted its New Drug Application (NDA) for plinabulin in combination with G-CSF for preventing chemotherapy-induced neutropenia (CIN), granting it Priority Review with a target action date of November 30, 2021. This combination aims to improve CIN prevention, addressing a significant medical need that affects up to 467,500 cancer patients annually. The NDA submission included pivotal Phase 3 data showing notable benefits over existing treatments, such as a 31.5% rate of preventing grade 4 neutropenia. The combination also demonstrated a reduction in severe adverse events and improved patient quality of life.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.51%
Tags
none
Beyondspring Inc

Nasdaq:BYSI

BYSI Rankings

BYSI Stock Data

52.81M
34.16M
15.21%
13.08%
4.74%
Biotechnology
Pharmaceutical Preparations
Link
United States
FLORHAM PARK